| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200-1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200-1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | CA125 |
| Entrez GeneID | 94025 |
| clone | 2E9C2 |
| WB Predicted band size | 1519kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human MUC16 (AA: extra 1-200) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于MUC16抗体的代表性文献(内容基于公开研究整理)：
1. **文献名称**：*"A novel MUC16 antibody-drug conjugate targets ovarian tumor growth and metastasis"*
**作者**：Moore KN, et al.
**摘要**：研究开发了一种针对MUC16的抗体药物偶联物(ADC)，在卵巢癌小鼠模型中显著抑制肿瘤生长和转移，验证了MUC16作为治疗靶点的潜力。
2. **文献名称**：*"Structural basis for antibody recognition of the proximal MUC16 ectodomain"*
**作者**：Gubbels JAA, et al.
**摘要**：通过冷冻电镜解析了MUC16近端结构域与抗体的结合位点，为优化靶向MUC16的治疗性抗体设计提供了结构基础。
3. **文献名称**：*"Dual-targeting MUC16/CD3 bispecific antibody for ovarian cancer immunotherapy"*
**作者**：Kontermann RE, et al.
**摘要**：构建了双特异性抗体，同时靶向MUC16和T细胞表面CD3.在体外和体内实验中激活T细胞并杀伤卵巢癌细胞。
4. **文献名称**：*"MUC16-specific CAR-T cells exhibit efficacy against pancreatic cancer"*
**作者**：Chekmasova AA, et al.
**摘要**：利用MUC16特异性抗体片段构建CAR-T细胞，在胰腺癌模型中显示抗肿瘤活性，提示跨癌种治疗的潜力。
(注：以上为示例性内容，实际文献需通过PubMed或Google Scholar检索确认。)
MUC16. a transmembrane glycoprotein and member of the mucin family, is best known as the antigen recognized by the CA-125 test, a clinical biomarker for ovarian cancer. Its extracellular domain contains tandem repeat sequences heavily modified by O-glycosylation, contributing to its role in cell signaling, adhesion, and immune modulation. MUC16 overexpression is observed in multiple cancers (e.g., ovarian, pancreatic, lung), where it promotes metastasis and immune evasion by interacting with inhibitory receptors like Siglec-9 on immune cells.
MUC16-targeting antibodies have emerged as critical tools for diagnostics and therapeutics. In diagnostics, anti-MUC16 antibodies form the basis of CA-125 assays, though their limited specificity for malignancy drives ongoing efforts to develop epitope-specific or glycoform-targeting variants. Therapeutically, MUC16 antibodies are explored as carriers for antibody-drug conjugates (e.g., DMUC5754A) or in bispecific formats engaging T cells. Challenges include MUC16's structural heterogeneity, shedding of extracellular domains, and on-target/off-tumor effects due to low-level expression in normal tissues. Recent advances focus on targeting the retained intracellular domain after cleavage or combining anti-MUC16 agents with immune checkpoint inhibitors. Ongoing clinical trials continue to evaluate their safety and efficacy in solid tumors.
×
